ELCC 2025 | Dr. Benjamin Besse Discusses De-escalation in Lung Cancer Treatment: How Far Are We From the Goal?

ELCC 2025 | Dr. Benjamin Besse Discusses De-escalation in Lung Cancer Treatment: How Far Are We From the Goal?

2025.04.11
At the 2025 European Lung Cancer Conference (ELCC), Professor Benjamin Besse from the Gustave Roussy Institute presented a report titled “Less is More: De-escalation Strategies in Patient Management and Clinical Trials.” He emphasized that while de-escalation strategies for drug treatments are still being actively explored, clinical applications face challenges, such as insufficient research funding.
Imaging, Heterogeneity & RCC Recurrence: Prof. Xiongjun Ye Shares Research Highlights at EAU25

Imaging, Heterogeneity & RCC Recurrence: Prof. Xiongjun Ye Shares Research Highlights at EAU25

2025.04.10
At #EAU25, Professor Xiongjun Ye (叶雄俊) from Peking Union Medical College Hospital shared his team’s latest findings on MRI accuracy in renal tumor diagnosis, tumor heterogeneity in RCC, and strategies for managing postoperative recurrence. His group’s EAU-selected research explores how imaging limitations and intratumoral heterogeneity affect treatment outcomes—offering new perspectives for optimizing RCC care.
Advancing MIBC Treatment: ADCs, AI Models & Bladder-Sparing Strategies

Advancing MIBC Treatment: ADCs, AI Models & Bladder-Sparing Strategies

2025.04.10
At #EAU25, we spoke with Prof. Haibin Chen and Prof. Ruiyi Zhang from Renji Hospital, Shanghai Jiao Tong University, who shared updates on their team's research in muscle-invasive bladder cancer (MIBC). They discussed a new study exploring ADC therapy for HER2+ MIBC, as well as progress in bladder-sparing treatment, ctDNA-based monitoring, and AI-driven molecular profiling for personalized treatment decisions.
Biopsy-Free Strategy in Prostate Cancer: Prof. Shousheng Chen at EAU25

Biopsy-Free Strategy in Prostate Cancer: Prof. Shousheng Chen at EAU25

2025.04.10
At hashtag#EAU25, Prof. Shousheng Chen (陈守臻) from Qilu Hospital of Shandong University shared key findings from his study on a "biopsy-free" diagnostic approach for prostate cancer using PSMA PET/CT, mpMRI, and serum biomarkers. He discussed how this strategy compares with traditional PSA and DRE, its potential in early diagnosis, and how it could guide follow-up and monitoring.
Bladder-Sparing vs. Radical Cystectomy – Prof. Liangyou Gu Shares Insights at EAU25

Bladder-Sparing vs. Radical Cystectomy – Prof. Liangyou Gu Shares Insights at EAU25

2025.04.10
At hashtag#EAU25 in Madrid, we had the opportunity to interview Professor Liangyou Gu from the General Hospital of the Chinese PLA, who shared his clinical perspective on emerging treatment strategies for muscle-invasive bladder cancer (MIBC). With ongoing breakthroughs in MIBC research, bladder-sparing approaches are gaining traction alongside radical cystectomy. Prof. Gu offered his insights on how clinicians can evaluate the best option for each patient, especially in the context of neoadjuvant therapy.
 EAU25 Interview Highlights | Prof. Samson Chan & Prof. Junlong Zhuang on PARPi in mHSPC

 EAU25 Interview Highlights | Prof. Samson Chan & Prof. Junlong Zhuang on PARPi in mHSPC

2025.04.10
At the 2025 EAU Congress, Prof. Junlong Zhuang (Nanjing Drum Tower Hospital) and Prof. Samson Chan (Department of Surgery, Tuen Mun Hospital, Hong Kong) sat down with Urology Frontier to discuss new insights from the Phase II PROact study. The study evaluated a triple combination of olaparib + abiraterone + prednisone in metastatic hormone-sensitive prostate cancer (mHSPC). According to the professors, early data show promising efficacy and manageable safety—suggesting PARP inhibitors may soon have a role beyond mCRPC in the prostate cancer treatment landscape. A potential step forward in precision therapy for prostate cancer. Watch the full interview now to hear their perspectives on the evolving role of PARPi in mHSPC.